$OGI

Cannabis Stock Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) Makes TSX Top Gainer List on Third Quarter Results

Organigram Global Inc. (OGI) reported Q3 fiscal 2026 results for the quarter ended June 30, 2026. The company said gross revenue rose to $145.1 million (+32% YoY), net revenue to $105.8 million (+49%), and adjusted EBITDA to $13.4 million (+136%). It cited Sanity Group’s acquisition contribution and noted a TSX share-price gain in early trading.

Original reporting
Published Aug 11, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cannabis Stock Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) Makes TSX Top Gainer List on Third Quarter Results — source image
Decision brief

The 30-second read

$OGIBullishMed
01

Why it matters

The reported acceleration in revenue and adjusted EBITDA, plus improved adjusted gross margin and Canadian operational efficiencies, is the core catalyst for re-pricing OGI. However, the cash flow profile (FCF outflow) and reliance on acquisition contributions may temper follow-through.

02

Market read

OGI’s Q3 results provide fresh, company-specific operating metrics and acquisition contribution details that can drive near-term trading and sentiment in cannabis equities.

03

What to watch

The article highlights non-cash fair value gains affecting net income, so traders may discount headline net income versus cash generation and sustainability of margins.

Relevance 7/10Novelty 6/10Timing: after-hours/early trading today following Q3 FY2026 results

Background

Organigram’s Q3 FY2026 includes the first quarter of financial contributions from its Sanity Group acquisition (closed April 15, 2026).

Company-level read

Ticker impact

$OGIBullishMedium confidence
Context

Organigram reported Q3 FY2026 results, including net revenue up 49% and adjusted EBITDA up 136%, with Sanity Group contributing since April 15.

Expected impact

Likely supports continued upside momentum versus prior expectations, but magnitude may fade if investors focus on free cash flow weakness and working-capital drag.

Evidence & confidence

The article provides multiple concrete operating metrics (revenue, adjusted EBITDA, margins) and ties them to acquisition contribution, but it lacks guidance, consensus context, or balance-sheet detail beyond FCF.

Market effects

Strong Canadian market-share claims plus European expansion progress may improve sentiment toward Canadian cannabis operators with international distribution platforms.

TSX-listed cannabis names may see sympathy flows if OGI’s results are viewed as evidence of sector stabilization.

European growth milestones tied to Sanity (Switzerland, Poland, UK) can influence how investors price cross-border cannabis platforms.

Counterpoint

Despite adjusted EBITDA growth, free cash flow was still an outflow, suggesting earnings quality may be pressured by working-capital needs.

Key entities

  • Organigram Global Inc.

    NASDAQ: OGI, TSX: OGI. Reported Q3 FY2026 results and first quarter of Sanity Group contributions.

  • Sanity Group

    Acquired April 15, 2026. Contributed approximately EUR25 million (C$40 million) net revenue in the quarter and advanced European expansion plans.

  • James Yamanaka

    CEO quoted on Q3 milestone and Sanity performance in line with expectations.

  • Paolo De Luca

    Named executive departing after nine years; previously CFO and Chief Strategy Officer.

Related articles

$ACBHighAI 9/10

Organigram Strikes A Deal to Acquire Aurora Cannabis

Organigram will acquire Aurora Cannabis for C$561 million (US$402 million), a 93% premium to Aurora's August 10 share price. Aurora shareholders will own 35% of the combined company. British American Tobacco will fund part of the deal. The acquisition aims to strengthen Organigram's position in the European cannabis market. Aurora's shares rose 21%, while Organigram's fell 2.6%.

$OGIHighAI 9/10

Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Topping Curaleaf’s Hostile Takeover Offer

Organigram will acquire Aurora Cannabis for C$561M (US$398M) at C$7.80 per share, a 93% premium over Aurora's unaffected price and 21% premium over Curaleaf's offer. The deal, approved by both boards, is expected to close in January 2027. Aurora shareholders can choose cash, stock, or a mix. British American Tobacco is financing part of the acquisition.